Claims
- 1. A compound of the formula I ##STR57## or pharmaceutically acceptable salts thereof; wherein
- A, B, D and E are each carbon atoms;
- X is --O--, --S--, --SO-- or --SO.sub.2 --;
- R.sub.1 and R.sub.2 are substituents on A, B, D or E when A, B, D or E are carbon and are independently selected from hydrogen; alkyl of 1 to 4 carbon atoms optionally substituted with substituents selected from amino, hydroxy or alkoxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms, halogen; hydroxy; haloalkyl; cyano; nitro; amino; alkylamino or dialkylamino of up to 6 carbon atoms; (dialkylamino)alkyl of 3 to 8 carbon atoms; alkanoyl of 1 to 4 carbon atoms; carbamoyl; (N-alkyl)carbamoyl or di(N-alkyl)carbamoyl of up to 7 carbon atoms; carboxy; alkoxycarbonyl of 1 to 4 carbon atoms; alkylthio of 1 to 6 carbon atoms; alkylsulphinyl of 1 to 6 carbon atoms; alkylsulphonyl of 1 to 6 carbon atoms;
- R.sub.3 is --CO.sub.2 H, --CO.sub.2 R.sub.7, --CHO, --CONHOR.sub.10, --CONHR.sub.8, --CONR.sub.8 R.sub.8 ', --CONH.sub.2 or --CONHSO.sub.2 CF.sub.3 ;
- R.sub.4 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, or an alkyl substituted with 1 or more fluorine atoms;
- R.sub.5 is an optional oxygen atom; ##STR58## R.sub.7 is alkyl, aryl, arylalkyl, aryloxyalkyl, --CH.sub.2 --COOR.sub.8 ##STR59## or indanyl; R.sub.8 and R.sub.8 ' are independently a lower alkyl;
- R.sub.9 is hydrogen, alkyl, perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl ##STR60## R.sub.10 is hydrogen, alkyl, aryl, arylalkyl or cycloalkyl; R.sub.11 is alkyl, aryl, arylalkyl or cycloalkyl;
- R.sub.12 is hydrogen, alkyl of 1 to 5 carbon atoms or phenyl;
- R.sub.13 is --CN, --NO.sub.2 or --CO.sub.2 R.sub.9 ;
- the term "alkyl" refers to both straight and branched chain groups having 1 to 10 carbon atoms;
- the term "alkenyl" and "alkynyl" refer to both straight and branched chain groups having 2 to 10 carbon atoms;
- the term "aryl" refers to phenyl or naphthyl or phenyl or naphthyl substituted with one or more substituents selected from halogen, alkyl, alkoxy, carboxy, alkylthio, hydroxy, alkanoyl, nitro, amino, alkylamino, dialkylamino or trifluoromethyl groups; and
- the term "cycloalkyl" refers to groups having 3 to 8 carbon atoms.
- 2. A compound of claim 1 wherein
- R.sub.1 and R.sub.2 are independently hydrogen, methyl, methoxy, chlorine or bromine;
- R.sub.3 is --COOH, --COOR.sub.7 where R.sub.7 is ethyl, propyl, butyl, ##STR61## where R.sub.10 and R.sub.11 are independently methyl, ethyl, isopropyl or t-butyl;
- R.sub.4 is methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, trifluoromethyl, or pentafluoroethyl;
- R.sub.5 is absent or is oxygen;
- R.sub.6 is 5-tetrazolyl, ##STR62## where R.sub.10 and R.sub.11 are defined as above;
- X is oxygen, sulfur or --SO.sub.2 ; and
- A, B, D and E are all carbon.
- 3. A compound of claim 1 wherein
- R.sub.1 and R.sub.2 are independently hydrogen, bromine or chlorine;
- R.sub.3 is --COOH or --COOR.sub.7 where R.sub.7 is ##STR63## where R.sub.10 is methyl or isopropyl and R.sub.11 is methyl, ethyl, t-butyl or isopropyl;
- R.sub.4 is methyl, ethyl, propyl, cyclopropyl or trifluoromethyl;
- R.sub.5 is absent or is oxygen;
- R.sub.6 is 5-tetrazolyl;
- X is oxygen; and
- A, B, D and E are all carbon.
- 4. A compound of claim 1, 2-Propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 5. A compound of claim 1, 2-Ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 6. A compound of claim 1, 2-Propyl-3-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, ethyl ester, or a pharmaceutically acceptable salt thereof.
- 7. A compound of claim 1, 2-Propyl-3-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, ethyl ester, 1-oxide, or a pharmaceutically acceptable salt thereof.
- 8. A compound of claim 1, 2-Propyl-3-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-methyl-1-(1-oxopropoxy)propyl ester, or a pharmaceutically acceptable salt thereof.
- 9. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 10. A compound of claim 1, 2-Ethyl-3-[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-methyl-1-(1-oxopropoxy)propyl ester, or a pharmaceutically acceptable salt thereof.
- 11. A compound of claim 1, 7-Chloro-2-(cyclopropyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 12. A compound of claim 1, 2-Cyclopropyl-6-fluoro-3-[[2'-(2H-tetrazol-5-yl-[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 13. A compound of claim 1, 2-Cyclopropyl-8-methyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 14. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4,5-quinolinedicarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 15. A compound of claim 1, 2-Propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, butyl ester, or a pharmaceutically acceptable salt thereof.
- 16. A compound of claim 1, 2-Propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-(1,1-dimethylethoxy)-2-oxoethyl ester, or a pharmaceutically acceptable salt thereof.
- 17. A compound of claim 1, 2-Ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-(1,1-dimethylethoxy)-2-oxoethyl ester, or a pharmaceutically acceptable salt thereof.
- 18. A compound of claim 1, 2-Ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, butyl ester, or a pharmaceutically acceptable salt thereof.
- 19. A compound of claim 1, 2-Ethyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 1-(2,2-dimethyl-1-oxopropoxy)-2-methylpropyl ester, or a pharmaceutically acceptable salt thereof.
- 20. A compound of claim 1, 2-Cyclopropyl-3-[[2'-[2-[1-(2,2-dimethyl-1-oxopropoxy)-2-methylpropyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 21. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, or a pharmaceutically acceptable salt thereof.
- 22. A compound of claim 1, 6-Bromo-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 23. A compound of claim 1, 2-Propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 1-oxide, or a pharmaceutically acceptable salt thereof.
- 24. A compound of claim 1, 6-Bromo-2-ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 25. A compound of claim 1, 2-Ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 1-oxide, or a pharmaceutically acceptable salt thereof.
- 26. A compound of claim 1, 2-Methyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 27. A compound of claim 1, 7-Chloro-2-ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, ethyl ester, or a pharmaceutically acceptable salt thereof.
- 28. A compound of claim 1, 7-Chloro-2-ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 29. A compound of claim 1, 2-Propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-(diethylamino)-2-oxoethyl ester, or a pharmaceutically acceptable salt thereof.
- 30. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-methyl-1-(1-oxopropoxy)propyl ester, or a pharmaceutically acceptable salt thereof.
- 31. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, ethyl ester, or a pharmaceutically acceptable salt thereof.
- 32. A compound of claim 1, 2-Cyclopropyl-6-methoxy-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 33. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-methyl-1-(2,2-dimethyl-1-oxopropoxy)propyl ester, or a pharmaceutically acceptable salt thereof.
- 34. A compound of claim 1, 2-Cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 1-(1-oxopropoxy)ethyl ester, or a pharmaceutically acceptable salt thereof.
- 35. A compound of claim 1, 2-Propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, 2-methyl-1-(2,2-dimethyl-1-oxopropoxy)propyl ester, or a pharmaceutically acceptable salt thereof.
- 36. A compound of claim 1, 2-Ethyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, ethyl ester, or a pharmaceutically acceptable salt thereof.
- 37. A compound of claim 1, 2-Cyclopropyl-5-methyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-4-quinolinecarboxylic acid, or a pharmaceutically acceptable salt thereof.
- 38. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 39. A method for treating hypertension comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 38.
- 40. A method for treating congestive heart failure comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 38.
- 41. A method for treating cardiac hypertrophy comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of claim 38.
Parent Case Info
This is a continuation of application Ser. No. 07/943,349, filed Sep. 10, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/837,782, filed Feb. 14, 1992, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4920131 |
Huang et al. |
Apr 1990 |
|
5157040 |
Greenlee et al. |
Oct 1992 |
|
5210204 |
Connor et al. |
May 1993 |
|
5369114 |
Roberts et al. |
Nov 1994 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0191603 |
Aug 1986 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
943349 |
Sep 1992 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
837782 |
Feb 1992 |
|